Infinity Pharmaceuticals, Inc. (INFIQ)
OTCMKTS
· Delayed Price · Currency is USD
0.0002
+0.0002 (1,900.00%)
Jan 23, 2025, 8:00 PM EST
Infinity Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2017 - 2013 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '23 Jun 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2017 - 2013 |
| Revenue | 2.57 | 2.59 | 1.86 | 1.72 | 3.05 | 22.15 | Upgrade
|
| Revenue Growth (YoY) | 15.88% | 39.56% | 8.09% | -43.62% | -86.23% | 269.10% | Upgrade
|
| Cost of Revenue | 28.53 | 33.97 | 32.77 | 27.8 | 34.42 | 19.83 | Upgrade
|
| Gross Profit | -25.96 | -31.38 | -30.91 | -26.08 | -31.38 | 2.32 | Upgrade
|
| Selling, General & Admin | 14.39 | 13.46 | 14.17 | 12.42 | 14.29 | 14.25 | Upgrade
|
| Operating Expenses | 14.39 | 13.46 | 14.17 | 12.42 | 14.29 | 14.25 | Upgrade
|
| Operating Income | -40.35 | -44.84 | -45.08 | -38.5 | -45.66 | -11.93 | Upgrade
|
| Interest Expense | -0.18 | -0.18 | -0.18 | -2.45 | -2.56 | -0.09 | Upgrade
|
| Interest & Investment Income | 1.28 | 0.66 | 0 | 0.45 | 1.12 | 0.77 | Upgrade
|
| EBT Excluding Unusual Items | -39.25 | -44.37 | -45.26 | -40.49 | -47.11 | -11.25 | Upgrade
|
| Merger & Restructuring Charges | -1.7 | - | - | - | - | - | Upgrade
|
| Pretax Income | -40.95 | -44.37 | -45.26 | -40.49 | -47.11 | -11.25 | Upgrade
|
| Income Tax Expense | - | - | - | - | -0.05 | - | Upgrade
|
| Net Income | -40.95 | -44.37 | -45.26 | -40.49 | -47.06 | -11.25 | Upgrade
|
| Net Income to Common | -40.95 | -44.37 | -45.26 | -40.49 | -47.06 | -11.25 | Upgrade
|
| Shares Outstanding (Basic) | 89 | 89 | 86 | 60 | 57 | 55 | Upgrade
|
| Shares Outstanding (Diluted) | 89 | 89 | 86 | 60 | 57 | 55 | Upgrade
|
| Shares Change (YoY) | 0.49% | 4.26% | 43.00% | 5.04% | 2.84% | 9.59% | Upgrade
|
| EPS (Basic) | -0.46 | -0.50 | -0.53 | -0.68 | -0.83 | -0.20 | Upgrade
|
| EPS (Diluted) | -0.46 | -0.50 | -0.53 | -0.68 | -0.83 | -0.20 | Upgrade
|
| Free Cash Flow | -38.88 | -42.45 | -40.63 | -35.78 | -43.86 | -4.71 | Upgrade
|
| Free Cash Flow Per Share | -0.43 | -0.48 | -0.47 | -0.60 | -0.77 | -0.09 | Upgrade
|
| Gross Margin | - | - | - | - | - | 10.47% | Upgrade
|
| Operating Margin | -1570.49% | -1729.43% | -2426.43% | -2239.50% | -1497.67% | -53.87% | Upgrade
|
| Profit Margin | -1593.93% | -1711.11% | -2436.06% | -2355.56% | -1543.36% | -50.81% | Upgrade
|
| Free Cash Flow Margin | -1513.59% | -1637.02% | -2186.71% | -2081.56% | -1438.41% | -21.29% | Upgrade
|
| EBITDA | -39.92 | -44.39 | -44.6 | -38.01 | -45.45 | -11.74 | Upgrade
|
| EBITDA Margin | - | - | - | - | - | -53.00% | Upgrade
|
| D&A For EBITDA | 0.43 | 0.46 | 0.48 | 0.48 | 0.22 | 0.19 | Upgrade
|
| EBIT | -40.35 | -44.84 | -45.08 | -38.5 | -45.66 | -11.93 | Upgrade
|
| EBIT Margin | - | - | - | - | - | -53.87% | Upgrade
|
| Revenue as Reported | - | - | - | - | 3.05 | 22.15 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.